Recursion Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $18,552 | $7,670 | $6,472 | $35,538 |
Gross Profit | 8,507 | -3,821 | -6,018 | 8,662 |
EBITDA | -123,176 | -112,530 | -102,085 | -88,624 |
EBIT | -130,697 | -121,758 | -108,102 | |
Net Income | -119,036 | -131,005 | -117,504 | -108,124 |
Net Change In Cash | 18,552 | 7,670 | 6,472 | 35,538 |
Free Cash Flow | -75,818 | -107,906 | -81,439 | -47,317 |
Cash | 549,853 | 545,683 | 654,473 | 743,294 |
Basic Shares | 543,000 | 532,460 | 529,303 | 526,719 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $74,681 | $58,839 | $43,876 | $39,681 |
Gross Profit | -46,273 | 13,601 | 1,289 | -8,594 |
EBITDA | -559,384 | -426,722 | -307,629 | -233,971 |
EBIT | -643,085 | -463,216 | -332,031 | -245,727 |
Net Income | -644,759 | -463,661 | -328,066 | -239,421 |
Net Change In Cash | 74,681 | 58,839 | 43,876 | 39,681 |
Free Cash Flow | -378,277 | -372,869 | -300,332 | -120,883 |
Cash | 743,294 | 594,350 | 391,565 | 549,912 |
Basic Shares | 447,446 | 274,207 | 207,853 | 175,537 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.22 |
2026-06-30 | -$0.25 |
2026-03-31 | -$0.22 |
2025-12-31 | -$0.21 |